



Combat Drugs Limited

Regd. Off: 4th Floor, Plot No. 94,
Sagar Society, Road No.2,
Banjara Hills, Hyderabad – 500 034
D.L.No.TG/15/04/2016-14766 /14767

Works: 9-109/9, Plot No.112,
Road No. 14, Gayatri Nagar,
Bouduppal, Hyd - 500039, T.S
CIN No.L24230TG1986PLC006781

Ph: (+91)-40-48536100
Url: www.combatdrugs.in
Email: info@combatdrugs.in
GST:36AAACC8372L1ZB

30th May, 2018

To,
The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001

Dear Sir,

Sub: Outcome of Board Meeting – Quarterly Results

Dear Sir,

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and all other applicable provisions and with reference to our letter dated 18th May, 2018, this is to inform you that the meeting of the Board of Directors of the company was held today ie; 30th May, 2018 at 04.30 P.M and concluded at 05.00 P.M., wherein the Board of directors of the company approved the Audited Financial Results (Stand Alone and Consolidated) for the quarter and Year Ended 31st March 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- 1) Statement of Audited Financial Results (Standalone and Consolidated) for the quarter and Year Ended 31st March 2018.
- 2) Auditors Report on Financial Results (Standalone and Consolidated).

Please Note that the opinion given by the Statutory Auditor in the Enclosed Audit Report is unmodified opinion.

We kindly request you to take the same on record and oblige.

Your Sincerely,

For **COMBAT DRUGS LIMITED**

SUSHANT MOHAN LAL
(DIRECTOR & COMPLIANCE OFFICER)



COMBAT DRUGS LIMITED (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society, Banjarahills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

Standalone Audited Financial Results For the Quarter and Year Ended 31st March, 2018

All amounts in ₹ Lakhs, unless otherwise stated

| Particulars | Quarter ended | | | Year ended | |
|---|---------------------|--------------|---------------------|---------------|----------------|
| | 31.03.2018 | 31.12.2017 | 31.03.2017 | 31.03.2018 | 31.03.2017 |
| | Audited (Note 3) | Unaudited | Audited (Note 3) | Audited | Audited |
| I. Revenue from operations | 31.77 | 15.06 | 9.27 | 50.42 | 37.50 |
| II. Other income | 11.54 | 28.13 | 0.00 | 62.58 | 0.00 |
| III. Total revenue (I + II) | 43.31 | 43.19 | 9.27 | 113.00 | 37.50 |
| IV. Expenses | | | | | |
| Cost of materials consumed | 30.49 | 12.93 | 6.73 | 43.42 | 26.44 |
| Changes in inventories of finished goods and stock in trade | (3.50) | - | - | (2.70) | - |
| Employee benefits expense | 1.99 | 9.78 | -0.48 | 24.94 | 15.7 |
| Other expenses | 11.61 | 9.52 | 2.22 | 29.10 | 13.8 |
| Total expenses | 40.59 | 32.23 | 8.47 | 94.76 | 55.94 |
| V. Profit/(Loss) before tax (III - IV) | 2.72 | 10.96 | 0.80 | 18.24 | (18.44) |
| VI. Tax expense: | | | | | |
| (1) Current tax | - | - | - | - | - |
| (2) Deferred tax | - | - | - | - | - |
| VII. Profit/(Loss) for the period (V-VI) | 2.72 | 10.96 | 0.80 | 18.24 | (18.44) |
| VIII. Other comprehensive income | - | - | - | - | - |
| IX. Total comprehensive income for the year | 2.72 | 10.96 | 0.80 | 18.24 | (18.44) |
| Paid Up Equity Share Capital (FV of Rs 10 each) | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 |
| X. Earning per equity | | | | | |
| (1) Basic | 0.03 | 0.14 | 0.01 | 0.23 | (0.23) |
| (2) Diluted | 0.03 | 0.14 | 0.01 | 0.23 | (0.23) |

Notes

- 1) The above results for the quarter and year ended 31 March 2018 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 30 May 2018
- 2) The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 and SEBI circular dated 5 July, 2016
- 3) The figures for the quarters ended 31 March 2018 and 31 March 2017 are the balancing figures between audited figures in respect of full financial years and the published unaudited year to date figures upto their quarter of the respective financial years. Also, the figures upto the end of the third quarter were only reviewed and not subjected to audit.
- 4) The Company has only one operating segment as per the requirements of Ind AS 108 "Operating Segments".
- 5) Reconciliation of the net profit for the quarter ended 31 March 2017 under the previous GAAP with the total comprehensive income as reported in these financial results under Ind AS is summarised here under:

| Particulars | Quarter Ended 31.03.2017 | Year Ended 31.03.2017 |
|---|-----------------------------|--------------------------|
| Net profit under previous GAAP | 0.80 | (18.44) |
| Add/(Less): Adjustments | - | - |
| Total comprehensive income under Ind AS | 0.80 | (18.44) |



For and on Behalf of the Board

Sushant Mohan Lal
DirectorPlace: Hyderabad
Date : 30.05.2018

COMBAT DRUGS LIMITED**(CIN CL23230TG1986PLC006781)****Regd.off: 4th Floor , Plot No.94,Sagar society**

Banjarahills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

Standalone Statement of Assets and Liabilities - Audited

| Particulars | 31 March 2018 | 31 March 2017 |
|-------------------------------------|----------------------|----------------------|
| I. ASSETS | | |
| Non-current Assets | | |
| (a) Financial assets | | |
| (i) Investments | 0.05 | - |
| (b) Other non-current assets | 0.30 | 221.95 |
| Current Assets | | |
| (a) Inventories | 9.73 | 7.03 |
| (b) Financial assets | | |
| (i) Trade receivables | 58.78 | 13.52 |
| (ii) Cash and cash equivalents | 2.29 | 3.46 |
| (c) Other current assets | 225.05 | 11.37 |
| TOTAL ASSETS | 296.20 | 257.34 |
| II. EQUITY AND LIABILITIES | | |
| Equity | | |
| (a) Equity share capital | 800.00 | 800.00 |
| (b) Other equity | (587.98) | (606.22) |
| Liabilities | | |
| Non-Current Liabilities | | |
| (a) Financial liabilities | | |
| (i) Borrowings | - | 4.79 |
| Current Liabilities | | |
| (a) Financial liabilities | | |
| (i) Borrowings | 13.30 | - |
| (ii) Trade payables | 55.89 | 46.17 |
| (iii) Other Financial liabilities | 14.42 | 5.70 |
| (b) Other current liabilities | 0.57 | 6.89 |
| TOTAL EQUITY AND LIABILITIES | 296.20 | 257.33 |

The reconciliation of equity as previously reported under the previous GAAP and as per Ind AS is summarised as here under:

| Particulars | 31.03.2017 |
|-----------------------------------|-------------------|
| Total equity as per previous GAAP | 193.78 |
| Less: | |
| Adjustments | - |
| Total equity as per Ind AS | 193.78 |

Place: Hyderabad
Date : 30.05.2018



For and on Behalf of the Board

Sushant Mohan Lal
Director

COMBAT DRUGS LIMITED

(CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society

Banjarahills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

Consolidated Audited Financial Results For the Quarter and Year Ended 31st March, 2018

All amounts in ₹ Lakhs, unless otherwise stated

| Particulars | Quarter ended | | Year ended |
|---|---------------------|--------------|---------------|
| | 31.03.2018 | 31.12.2017 | 31.03.2018 |
| | Audited (Note 3) | Unaudited | Audited |
| I. Revenue from operations | 31.77 | 15.06 | 50.42 |
| II. Other income | 11.54 | 28.13 | 62.58 |
| III.Total revenue (I + II) | 43.31 | 43.19 | 113.00 |
| IV. Expenses | | | |
| Cost of materials consumed | 30.49 | 12.93 | 43.42 |
| Purchases of Stock-in-Trade | 0.00 | - | 0.00 |
| Changes in inventories of finished goods and stock in trade | (3.50) | - | (2.70) |
| Employee benefits expense | 1.99 | 9.78 | 24.94 |
| Other expenses | 11.61 | 9.52 | 29.10 |
| Total expenses | 40.59 | 32.23 | 94.76 |
| V. Profit/(Loss) before tax (III - IV) | 2.72 | 10.96 | 18.24 |
| VI. Tax expense: | | | |
| (1) Current tax | - | - | - |
| (2) Deferred tax | - | - | - |
| VII. Profit/(Loss) for the period (V-VI) | 2.72 | 10.96 | 18.24 |
| VIII. Other comprehensive income | - | - | 0.00 |
| | 2.72 | 10.96 | 18.24 |
| IX. Total comprehensive income for the year | | | |
| Paid Up Equity Share Capital (FV of Rs 10 each) | 800.00 | 800.00 | 800.00 |
| X. Earning per equity | | | |
| (1) Basic | 0.03 | 0.14 | 0.23 |
| (2) Diluted | 0.03 | 0.14 | 0.23 |

Notes

- 1) The above results for the quarter and year ended 31 March 2018 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 30 May 2018
- 2) The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 and SEBI circular
- 3) The figures for the quarters ended 31 March 2018 and 31 March 2017 are the balancing figures between audited figures in respect of full financial years and the published unaudited year to date figures upto their quarter of the respective financial years. Also, the figures upto the end of the third quarter were only reviewed and not subjected to audit.
- 4) The Company has only one operating segment as per the requirements of Ind AS 108 "Operating Segments".
- 5) Previous year figures are not presented as Consolidation is applicable during the current year.



For and on Behalf of the Board

Sushant Mohan Lal
DirectorPlace: Hyderabad
Date : 30.05.2018

COMBAT DRUGS LIMITED

(CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society

Banjarahills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

Consolidated Statement of Assets and Liabilities - Audited**All amounts in ₹ Lakhs, unless otherwise stated**

| Particulars | 31 March 2018 |
|-------------------------------------|----------------------|
| I. ASSETS | |
| Non-current Assets | |
| (a) Other non-current assets | 0.30 |
| Current Assets | |
| (a) Inventories | 9.73 |
| (b) Financial assets | |
| (i) Trade receivables | 58.78 |
| (ii) Cash and cash equivalents | 2.29 |
| (c) Other current assets | 225.10 |
| TOTAL ASSETS | 296.20 |
| II. EQUITY AND LIABILITIES | |
| Equity | |
| (a) Equity share capital | 800.00 |
| (b) Other equity | (587.98) |
| Liabilities | |
| Current Liabilities | |
| (a) Financial liabilities | |
| (i) Borrowings | 13.30 |
| (ii) Trade payables | 55.89 |
| (iii) Other Financial liabilities | 14.42 |
| (b) Other current liabilities | 0.57 |
| TOTAL EQUITY AND LIABILITIES | 296.20 |

Previous year figures not given as Consolidation is applicable only in the current year.



For and on Behalf of the Board

Place: Hyderabad

Date: 30.05.2018

Sushant Mohan Lal
Director

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Report on the Annual Standalone Financial Results of Combat
Drugs Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

To
The Board of Directors of **Combat Drugs Limited**

We have audited the annual standalone financial results ("the Statement") of Combat Drugs Limited ("the Company") for the year ended 31st March, 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the quarter ended 31st March, 2018 and corresponding quarter ended in the previous year as reported in the Statement are the balancing figures between audited figures in respect of full financial year and the published year to date figures up to the end of third quarter of the relevant financial year. Also, the figures up to the end of third quarter of the respective financial years had only been reviewed and not subject to audit.

This Statement has been prepared on the basis of the Ind AS annual financial statements and reviewed unaudited quarterly financial results up to the end of the third quarter, which is the responsibility of the Company's Management. Our responsibility is to express an opinion on the Statement based on our audit of the Ind AS annual financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), specified under Section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued there under and other accounting principles generally accepted in India and in compliance with requirements of Regulation 33 of SEBI Regulations, 2015.

We conducted our audit in accordance with the Standards on Auditing generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatements. An audit includes examining, on a test check basis, evidence supporting the amounts disclosed in the Statement. An audit also includes assessing the accounting principles used and significant estimates made by Management. We believe that our audit provides a reasonable basis for our opinion.



Based on our audit conducted as above, in our opinion and to the best of our information and according to the explanations given to us, the Statement:

- (i) is presented in accordance with the requirements of Regulation 33 of the SEBI Regulations, 2015 and SEBI circular dated 5 July 2016; and
- (ii) gives a true and fair view of the financial performance including other comprehensive income and other financial information for the year ended 31 March 2018.

For M.Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)


A.V.Sadasiva

Partner

Membership Number.018404



Place: Secunderabad

Date: 30.05.2018

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

Independent Auditor's Report on the Annual Consolidated Financial Results of Combat Drugs Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of **Combat Drugs Limited**

1. We have audited the annual accompanying consolidated financial results ("Consolidated Results") of **Combat Drugs Limited** ("the Parent") and its wholly owned subsidiary (the Parent and its wholly owned subsidiary together referred to as "the Group") for the quarter and year ended 31st March, 2018 included in the accompanying statement of consolidated financial results ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016.

The Consolidated Results included in the Statement, which are the responsibility of the Parent's Management ("Management") and approved by the Board of Directors, have been compiled from the related consolidated financial statements which have been prepared in accordance with the Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Consolidated Results included in the Statement, based on our audit of such consolidated financial statements.

2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Consolidated Results included in the Statement are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Consolidated Results included in the Statement. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Consolidated Results included in the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers



internal financial control relevant to the Parent's preparation and fair presentation of the Consolidated Results included in the Statement In order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal financial control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Consolidated Results included in the Statement.

We believe that the audit evidence obtained by us and the audit evidence obtained by the auditors in terms of their reports referred to in paragraph 4 below, is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate financial statements of the subsidiaries referred to in paragraph 5 below, the Consolidated Results included in the Statement:
 - a) includes the results of Wholly Owned Subsidiary RA Labs Pte. Ltd, Singapore
 - b) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016; and
 - c) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit, total comprehensive income and other financial information of the Group for the year ended 31st March, 2018.
5. The Statement includes financial results/statements and other financial information of the wholly owned subsidiary, which reflect total assets of Rs. 3.56 lakhs as at 31st March, 2018, total revenues of Rs. Nil, total net profit of Rs. Nil and total comprehensive income of Rs. Nil for the year ended 31st March, 2018. Such financial information has been prepared in accordance with accounting principles generally accepted in its country and which has not been audited and which is certified by the Management. The Management has converted the financial statements of this subsidiary from accounting principles generally accepted in its country to accounting principles generally accepted in India. In our opinion and according to the information and explanations given to us by the




Management, these financial results and other financial information are not material to the Group. Our opinion is not modified in respect of this matter.

6. Attention is drawn to the fact that the figures for the quarter ended 31st March, 2018 as reported in the Statement are the balancing figures between audited figures in respect of full financial year and the published year to date figures up to the end of third quarter.

For M.Anandam & Co.,
Chartered Accountants

(Firm Regn.No.0001255)



A.V.Sadasiva

Partner

Membership Number.018404



Place: Secunderabad

Date: 30.05.2018



Combat Drugs Limited

Regd. Off: 4th Floor, Plot No. 94,
Sagar Society, Road No.2,
Banjara Hills, Hyderabad – 500 034
D.L.No.TG/15/04/2016-14766 /14767

Works: 9-109/9, Plot No.112,
Road No. 14, Gayatri Nagar,
Bouduppal, Hyd - 500039, T.S
CIN No.L24230TG1986PLC006781

Ph: (+91)-40-48536100
Url: www.combatdrugs.in
Email: info@combatdrugs.in
GST:36AAACC8372L1ZB

30/05/18

DECLARATION

(Pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Amendment Regulations, 2016 and SEBI Circular No-CIR/CFD/CMD/56/2016)

In compliance with the Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI (Listing Obligations and Disclosure Requirements) Amendment Regulations, 2016 and SEBI Circular No-CIR/CFD/CMD/56/2016, we hereby declare that Auditor of the Company M/s M. Anandam & Co, Chartered Accountants have issued Audit Report for the quarter and financial Year ended 31st March 2018 with unmodified opinion on the Financial Statements of the Company as prepared under the provisions of Companies Act, 2013 and SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the financial year ended March 31, 2018.

Your Sincerely

For **COMBAT DRUGS LIMITED**

SUSHANT MOHAN LAL

(DIRECTOR)

DIN: 01227151

